Gabelli Funds’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Gabelli Funds’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-235,396	Closed	-$2.43M	–	1157
2023 Q2	$2.43M	Sell	235,396 -10,000	-4%	-$102K	0.02%	617
2023 Q1	$2.49M	Sell	245,396 -35,000	-12%	-$353K	0.02%	616
2022 Q4	$2.79M	Hold	280,396	–	–	0.02%	586
2022 Q3	$2.73M	Buy	280,396 +180,000	+179%	+$1.76M	0.02%	589
2022 Q2	$975K	Hold	100,396	–	–	0.01%	861
2022 Q1	$974K	Hold	100,396	–	–	0.01%	895
2021 Q4	$970K	Hold	100,396	–	–	0.01%	918
2021 Q3	$973K	Buy	+100,396	New	+$979K	0.01%	913

Other funds holding NKGN

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

KIM

Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AIMCA

Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $16.7B AUM 23.27% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Gabelli Funds's NKGN Position: Q3 2023 in Review

Gabelli Funds sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q3 2023, closing a stake of 235,396 shares — an estimated $2.43M sold.

Gabelli Funds first reported a position in NKGN in Q3 2021 and held it in 8 quarters. The position peaked at $2.79M in Q4 2022. 13 funds tracked by Wall St. Rank hold NKGN as of Q3 2023.

Gabelli Funds reported no remaining NKGen Biotech, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Gabelli Funds sold 235,396 NKGen Biotech, Inc. Common Stock shares in Q3 2023, an estimated $2.43M.
Gabelli Funds first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Gabelli Funds's NKGen Biotech, Inc. Common Stock position peaked at $2.79M in Q4 2022.
13 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q3 2023.

Based on Gabelli Funds's 13F filing for Q3 2023, filed 8 Nov 2023.